Projects    »    

A novel cancer therapy: hTERT – CRISPR/Cas9

A novel cancer therapy: hTERT – CRISPR/Cas9

I propose halting telomerase production in cancer cells via CRISPRCas9. Telomerase preserves telomeres preventing cancer cells from reaching the Hayflick limit and succumbing to apoptosis. A functional telomerase inhibitor would be a viable way to combat cancer. Should telomerase production cease, the Hayflick limit would be reached within a few rounds of mitosis. I propose eradicating a vital telomerase component, hTERT, via CRISPRCas9. Cas9 and sgRNA will be administered in a lipid nanoparticle. The process set forth by myself is theoretically viable and apt for mass production. I have laid out a research plan, which, if followed, could prove the viability of my solution in vitro. Existing scientific knowledge suggests that my proposition is theoretically valid both in vitro and in vivo.

Adam Yousfi

16 years


Share on Social Media

Watch the Award Cermony

17 September from 13:00 – 14:30